Trial Profile
Phase IIb trial of EVT-201 for treatment of insomnia in China
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Dimdazenil (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Zhejiang Jingxin Pharmaceutical
- 14 Mar 2015 Status changed from not yet recruiting to recruiting in 2014, according to an Evotec media release.
- 12 Aug 2014 According to an Evotec media release, JingXin Pharmaceutical Co., Ltd, received approval from the China State Food and Drug Administration (SFDA) for this study and plans to start in the second half of 2014.
- 09 Aug 2013 According to an Evotec media release, Zhejiang JingXin Pharmaceutical was granted permission in April 2013 by the Chinese Center of Drug Evaluation (CDE) to commence clinical trials of EVT 201.